Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth Post published:July 27, 2022 Post category:Press Release
Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond Post published:June 24, 2022 Post category:Press Release
Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin Post published:December 14, 2021 Post category:Press Release
Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial Post published:November 2, 2021 Post category:Press Release
Braxia Scientific Introduces “Braxia Health” a Growing Network of Clinics Leading Novel Psychedelic Research and Treatments for Mental Disorders Post published:May 5, 2021 Post category:Press Release
Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities Post published:May 3, 2021 Post category:Press Release